{"id":"NCT03182686","sponsor":"Ampio Pharmaceuticals. Inc.","briefTitle":"AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee","officialTitle":"A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-19","primaryCompletion":"2017-12-07","completion":"2017-12-07","firstPosted":"2017-06-09","resultsPosted":"2022-08-08","lastUpdate":"2022-08-09"},"enrollment":168,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee","Knee Osteoarthritis","Knee Arthritis","Knee Pain Chronic"],"interventions":[{"type":"BIOLOGICAL","name":"4 mL injection of Ampion","otherNames":[]},{"type":"DRUG","name":"4 mL Injection of Placebo","otherNames":["0.9% Saline"]}],"arms":[{"label":"AMPION™ 4 mL dose","type":"EXPERIMENTAL"},{"label":"Placebo 4 mL dose","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.","primaryOutcome":{"measure":"Number of Participants Classified as Responders","timeFrame":"Determined from Baseline to 12 Weeks","effectByArm":[{"arm":"Ampion 4 mL Dose","deltaMin":102,"sd":null},{"arm":"Saline 4 mL Dose","deltaMin":15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":14},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["29910837"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":144},"commonTop":["Arthralgia","Joint stiffness","Viral upper respiratory tract infection","Joint swelling","Basal cell carcinoma"]}}